Skip to Navigation
Skip to Main Content
Skip to Related Content
to view your mail
Yahoo Finance Plus
U.S. markets closed
Russell 2000 Futures
Pro-Dex, Inc. (PDEX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 4:00PM EDT
48 reactions on $PDEX conversation
Sign in to post a message.
Their volume was 4k over their average today, holding on to see what's in store
This is a very Bullish Chart, traders! 💰💵📈
One customer is the majority of their business. Anything happens to that one customer, and that's the end of PDEX. PDEX is cheap and growing, but seems like it deserves a very low multiple since they have most of their eggs in one basket, and we don't know if that company expects to keep growing. Their future is not mostly determined by their own efforts, like most companies, but some other company and does anyone even know who that company is?
PDEX worth $25- here's why
Backlog up 140% in two qtrs, EPS up 200% in two qtrs, pristine balance sheet, and in the medical device sector which supports a 25-40 PE. Their largest customer is supposed to ramp up orders in early 2019 according to the Sept qtr 10Q as well. So those wondering if the growth can continue, I would say things look good well into 2019. EPS will likely increase over the $.31 Sept qtr in the Dec qtr for the huge backlog, I believe PDEX will make $2-$2.50 in 2019, and could climb to the $40-$50 area. However for now with $1.24 going forward, based on the Sept qtr annualized, I think a 20 PE is appropriate- $25 target.
Does anyone know what going on? A drop of ~30% when it beats estimates and does much better YoY?
.28 cent for the quarter. Training 12 months is now .92 cent. For fiscal 2019 PDEX has already earned .59c and have a new product launch scheduled for March 2019. But get this:
Finally," concluded Mr. Van Kirk, "we are pleased to announce that on February 4, 2019, the customer with whom we entered into a development contract in early fiscal 2019, executed a material procurement authorization in the amount of $3.4 million to support production orders for the private-labeled thoracic driver and related accessories, which we expect to ship in calendar 2019."
At $16 a share the company would be trading at 17 X sales. Given their rapid growth you can easily build a case for a much higher multiple. Also, with the procurement news today you can take comfort that the train will keep rolling.
Technically, more my background, a trade through $16 a share on heavy volume would have the chart bring $21 a share intoplay short term. With PDEX's low float and explosive growth you could see an extraordinary move in share price at some point.
I would be very interested to hear what PDEX is going to do with the $5 million bank loan they just received + a $2 million revolver.
Sounds like great news!!
A lot of insiders selling. Take a look at their fillings.
Not sure who would be selling in the $13's, but thanks for the cheap shares. Backlog over the last 4 quarters has risen sequentially from $7.3M to $12.3M to $17.1M to $25M(!). And that doesn't include a $3.4M order received in February for their new thoracic driver. Sales for this product could now begin to ramp higher through 2020, and carry higher margins.
Looking forward to what should be a terrific fiscal Q3 comp in early May. Think PDEX will post a .30+ quarter vs. .11/share last year on 25%+ revenue growth. And they'll have several dollars of cash & investments on the balance sheet. That report should send PDEX to new 52-week highs over $16. And who knows how high when momentum traders start buying this undervalued stock in the hot medical device sector. With that monster backlog, traders will excitedly wonder how big the earnings will be when PDEX posts quarterly revenues of $8M, $9M, $10M etc.
This one is still in the early stages imo. A year from now I wouldn't be surprised if PDEX was double or triple the current price.
CEO just purchased 3500 shares today.
From the Mar qtr 10Q- largest customer contract extension through 2021
More good news here for those concerned of customer concentration. This from the Mar qtr 10Q...
" At March 31, 2018, we had a backlog of approximately $7.3 million, of which $5.3 million is scheduled to be delivered in fiscal 2018 and the balance is scheduled to be delivered next fiscal year. We may experience variability in our new order bookings due to various reasons, including, but not limited to, the timing of major new product launches and customer planned inventory builds. For instance, our largest customer sent a purchase order in April 2018 in the amount of $5.7 million for products scheduled to be delivered in the fiscal 2019. Separately, in January 2018, this customer executed a contract extension for an additional three years of deliveries, at continued volumes of 150 units per month, through the end of calendar 2021. However, we do not typically experience seasonal fluctuations in our shipments and revenues. "
Who is selling this stock !
59% revenue increase. This validates their ability to build and market their own products. Bigger and better products coming
M&M's took over.
They have invested roughly $1.5 million in Air T, Inc shares. Hopefully, the loss on this investment will not exceed the profit of their actual business this quarter. Maybe they`d better stick to their business and use their surplus cash for stock buybacks and a dividend.
What is happening here. Why the huge drop
The company couldn't ship their new product because of problems, and they are getting squeezed on margins by their existing customers. If something good happens here it will take longer to play out.
Just need another customer?
Following an outstanding earnings report yesterday, PDEX has traded almost the average daily volume of shares within the first 10 minutes. And, the stock is up by 6.7% so far.
Iran Ready To Deliver "Crushing" Military Response After Tanker Attack
Take-Two beats on top and bottom line, but Q2 revenue forecasts falls short
Yahoo Finance Video
Little Island in NYC ‘turned out far better than I had hoped,’ Barry Diller says
Advertise with us
© 2021 Verizon Media. All rights reserved.
About Our Ads
Discover new investment ideas by accessing unbiased, in-depth investment research